Most of the risks belong to the hormone, not the route. Rising red cell mass, blood pressure changes, prostate effects, venous clots, and suppressed sperm production show up on the labeling of every injectable testosterone product regardless of how it goes in. Route mainly changes local reactions and, on some measures, the size of the peaks.
The warnings that follow the drug everywhere
Product labeling for the subcutaneous testosterone enanthate auto-injector lists polycythemia, venous thromboembolism including deep vein thrombosis and pulmonary embolism, worsening of benign prostatic hyperplasia with a potential prostate cancer risk, blood pressure increases, edema, abuse potential, and effects on sperm production. The intramuscular esters carry an overlapping set. None of those are route-specific findings, and no injection technique avoids them.
One label detail is worth stating precisely because it changed recently. The auto-injector previously carried a boxed warning about blood pressure increases. That boxed warning was removed in March 2025, and blood pressure was retained in the warnings and precautions section instead. The signal did not vanish; its labeling position changed, and blood pressure is still something a prescriber measures periodically.
How openly a provider documents these risks is itself worth comparing. Adverse-effect information is presented very differently across telehealth categories, and patients researching options can learn a lot from the depth of it. In the weight-management space, for instance, services such as Henry Meds, Ro, and HealthRX, whose GLP-1 side effects overview catalogs what to watch for, set a transparency bar that is reasonable to expect from any men’s health program as well.
Red cell mass is the effect that drives the schedule
Exogenous testosterone stimulates erythropoiesis. That is why hematocrit monitoring, rather than symptom reporting, sets the rhythm of follow-up. The subcutaneous auto-injector label directs clinicians to check hematocrit approximately every 3 months to detect increased red cell mass and polycythemia, and the intramuscular products are monitored on comparable logic.
A narrative review in Sexual Medicine Reviews examined how hematocrit is managed in this population, and a systematic review in Blood Advances placed testosterone within the broader category of drug-induced erythrocytosis. The clinical concern is not the number itself but what elevated red cell mass can lead to. A case report in Cureus described cerebral venous sinus thrombosis attributed to secondary polycythemia in someone using testosterone, which is the kind of event routine monitoring exists to prevent.
Where the two routes genuinely differ
Comparative evidence is limited but consistent in direction. A study of 234 hypogonadal men published in the Journal of Urology compared intramuscular testosterone cypionate with a subcutaneous testosterone enanthate auto-injector. Both groups saw significant increases in trough total testosterone, and after adjustment the delivery method was not independently associated with total testosterone. The auto-injector was independently associated with lower post-treatment estradiol and lower hematocrit, and neither method was associated with a significant rise in prostate specific antigen.
The other difference is local. Reactions at the site of administration, and the discomfort of the process itself, are reported differently between routes. A small crossover pilot in the American Journal of Health-System Pharmacy found that participants moving from intramuscular to subcutaneous administration reported less anxiety beforehand and less pain during and afterward, with total testosterone exposure broadly comparable.
Fertility suppression is the consequence people are told about least
Testosterone given from outside suppresses the hypothalamic-pituitary-gonadal axis. Luteinizing hormone and follicle-stimulating hormone fall, intratesticular testosterone falls with them, and sperm production is impaired. A clinician’s guide in Asian Journal of Andrology describes azoospermia as a well-documented consequence of exogenous testosterone that can be temporary or permanent depending on the individual and how long treatment ran.
This applies to both routes equally. It is not a rare adverse event, it is an expected pharmacologic effect, and it is the single thing most worth raising before a first prescription rather than after.
What a monitoring plan should contain
Before agreeing to anything, it is fair to ask what the follow-up actually looks like and who is paying attention to it. Telehealth men’s health services differ sharply here, and the schedule is set by the provider behind it rather than by the route chosen. A program that ships product without a defined lab cadence is offering something different from one that reassesses on a set interval.
| What is checked | Why it matters | Route dependent? |
|---|---|---|
| Hematocrit | Detects rising red cell mass and polycythemia | Same test, some evidence of different magnitude |
| Total testosterone | Confirms the treatment is landing in range | Timing of the draw differs by product |
| Blood pressure | Listed in warnings for these products | No |
| Prostate assessment | Benign prostatic hyperplasia and prostate monitoring | No |
| Symptoms of clot | Deep vein thrombosis and pulmonary embolism reports | No |
| Injection site | Local reactions differ between the two routes | Yes |
What the cardiovascular evidence does and does not say
The largest randomized safety trial in this field, TRAVERSE, enrolled 5,246 men aged 45 to 80 with symptoms of hypogonadism, two fasting testosterone results below 300 ng per deciliter, and either existing cardiovascular disease or high risk of it. Testosterone was noninferior to placebo for the primary composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. The investigators also observed a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group.
Two caveats belong with that result. The trial used a transdermal gel, not an injection, so it does not settle questions specific to either injectable route. And it studied men who met a diagnostic threshold, which is a different population from men taking testosterone without a diagnosis.
Frequently asked questions
Does subcutaneous administration cause fewer side effects overall?
Not overall. The systemic warnings are the same. Comparative data point to lower post-treatment hematocrit and estradiol with the subcutaneous auto-injector and to better reported tolerability of the process, but the prostate, clot, blood pressure, and fertility considerations do not change with route.
How often should blood work be repeated?
Labeling for the subcutaneous auto-injector specifies hematocrit checks at roughly three-month intervals, and endocrine society guidance describes ongoing review of symptoms, testosterone concentrations, hematocrit, and prostate health. The exact schedule is individualized, so it should be written down at the start rather than left open.
What symptoms warrant contacting a prescriber quickly?
Swelling, pain, warmth or redness in a leg, sudden shortness of breath, chest pain, severe headache, or vision changes are the ones the labeling flags. Those relate to clotting and to elevated red cell mass, and they should not wait for the next scheduled appointment.
Is a high hematocrit reason to stop?
It is reason for a clinical decision, not a self-directed one. Responses range from closer monitoring to changing the product to pausing therapy, and published reviews describe a range of management approaches. The reading is interpreted together with the trend and the person’s other risks.
Does the site reaction pattern differ between routes?
Yes. Local reactions are the clearest route-dependent difference, and reported experience of the procedure differs too. That is worth mentioning at follow-up, because tolerability is one of the main reasons people stop treatment that is otherwise working.
